Neurofilament light chain (NfL) did not predict early progression in this cohort, supporting the concept that disability accumulation may be driven by smoldering, non-relapse mechanisms
Early movers in this direction are already demonstrating better outcomes and higher patient satisfaction
CJC-1295 is a modified Growth Hormone Releasing Hormone (GHRH) analog, engineered with a Drug Affinity Complex (DAC) that allows it to bind to albumin in the blood, extending its activity in the body
M L Ezhilarasan Reviewed by Dr
A future study should compare levels of GSH in plasma and brain following NAC administration
Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R (2012a) A randomized controlled pilot trial of oral N-acetylcysteine in children with autism